Welcome to Business Outlook
Related Articles
Incepta Vaccine is producing a vaccine safeguarding against cervical cancer at a Savar plant by importing the main ingredients.
Papilovax safeguards against human papillomavirus (HPV), a very common group of viruses that do not cause any problems in most people but some of which can cause genital warts or cancer, including that of the cervix cells in women.
The Tk 200-crore plant can produce 180 million doses a year, each costing Tk 2,500. The vaccine can be administered to healthy women from nine years to 45 years. Each person requires two doses.
Papilovax is marketed in pre-filled syringes “manufactured in aseptic environment and marketed at controlled temperature in fully sterile packaging”, said the company.
Direct administration of vaccine in pre-filled syringes is easy and does not require separate dosing. As a result, the vaccine can be administered more safely and easily at the correct dose, it added.
“We are working with Imperial College in England to manufacture the main ingredient of this vaccine at our plant,” Abdul Muktadir, chairman and managing director of Incepta Pharmaceuticals, told The Daily Star.
Incepta Vaccine announced of embarking on the production through an event at Pan Pacific Sonargaon Dhaka yesterday.
Every year over 10,000 women die of cervical cancer in Bangladesh and over 5 crore women are at risk of it. Ignorance and years of neglect are to blame.
National Prof Shahla Khatun said the price was quite high for many, especially people with low incomes.
(TDS)
